CN113874397A - 利用鉴定的腺苷指纹治疗癌症 - Google Patents

利用鉴定的腺苷指纹治疗癌症 Download PDF

Info

Publication number
CN113874397A
CN113874397A CN202080037139.7A CN202080037139A CN113874397A CN 113874397 A CN113874397 A CN 113874397A CN 202080037139 A CN202080037139 A CN 202080037139A CN 113874397 A CN113874397 A CN 113874397A
Authority
CN
China
Prior art keywords
cancer
adenosine
subject
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080037139.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·安德森
D·阿肖克
D·M·迪里恩佐
A·R·乌迪亚瓦尔
M·J·沃尔特斯
S·W·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcus Biosciences Inc
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CN113874397A publication Critical patent/CN113874397A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080037139.7A 2019-03-29 2020-03-27 利用鉴定的腺苷指纹治疗癌症 Pending CN113874397A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826728P 2019-03-29 2019-03-29
US62/826,728 2019-03-29
PCT/US2020/025242 WO2020205527A1 (en) 2019-03-29 2020-03-27 Treatment of cancer utilizing an identified adenosine fingerprint

Publications (1)

Publication Number Publication Date
CN113874397A true CN113874397A (zh) 2021-12-31

Family

ID=72666937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080037139.7A Pending CN113874397A (zh) 2019-03-29 2020-03-27 利用鉴定的腺苷指纹治疗癌症

Country Status (8)

Country Link
US (2) US12310965B2 (https=)
EP (1) EP3947463A4 (https=)
JP (1) JP7743309B2 (https=)
KR (1) KR20210144821A (https=)
CN (1) CN113874397A (https=)
AU (1) AU2020256098A1 (https=)
CA (1) CA3135487A1 (https=)
WO (1) WO2020205527A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
CN113795267A (zh) 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
WO2021247188A1 (en) * 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
KR20230026312A (ko) 2020-06-17 2023-02-24 아르커스 바이오사이언시즈 인코포레이티드 Cd73 억제제의 결정형 및 이의 용도
EP4294948A1 (en) * 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
AU2022347682B2 (en) * 2021-09-15 2025-08-28 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof
US20240180947A1 (en) 2022-10-20 2024-06-06 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031320A1 (en) * 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
US20160129108A1 (en) * 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
WO2017152085A1 (en) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
CN107286146A (zh) * 2017-07-05 2017-10-24 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4‑氨基嘧啶衍生物及其用途
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
US20180200378A1 (en) * 2017-01-06 2018-07-19 Bicycle Therapeutics Limited Compounds for treating cancer
US20180215730A1 (en) * 2017-01-20 2018-08-02 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
WO2018187484A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
CN108697719A (zh) * 2016-01-08 2018-10-23 艾库斯生物科学有限公司 胞外5′-核苷酸酶的调节剂及其用途
CN108780084A (zh) * 2015-09-03 2018-11-09 诺华股份有限公司 预测细胞因子释放综合征的生物标志物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2009519236A (ja) 2005-11-30 2009-05-14 キャン−ファイト・バイオファーマ・リミテッド Ａ３アデノシンレセプター抗体の治療的使用
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9307487B2 (en) 2013-08-30 2016-04-05 Qualcomm Incorporated Methods and systems for improved utilization of a wireless medium
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018094148A1 (en) 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
EP3600273A4 (en) 2017-03-31 2021-01-20 Peloton Therapeutics, Inc. CD73 INHIBITORS AND USES THEREOF
US20190022096A1 (en) 2017-04-04 2019-01-24 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
ES2953349T3 (es) 2017-05-05 2023-11-10 Arcus Biosciences Inc Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
PL3634417T3 (pl) 2017-05-17 2023-09-25 Arcus Biosciences, Inc. Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
CN110997722B (zh) 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
KR102770110B1 (ko) 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 Cd38 항체
CA3073085A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 modulating antibody
KR20200096921A (ko) 2017-11-06 2020-08-14 코버스 파마슈티칼스, 인크. 암 치료를 위한 아데노신 경로 억제제
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
CN112004541A (zh) 2018-03-09 2020-11-27 艾库斯生物科学有限公司 肠道外给药的免疫增强药物
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
PL3829581T3 (pl) 2018-07-27 2024-07-01 Arcus Biosciences, Inc. Antagoniści pirydonu a2r
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
CA3115607A1 (en) 2018-10-11 2020-04-16 Pfizer Inc. Dosage regimen for tfpi antagonists
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
CN113795267A (zh) 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TW202135823A (zh) * 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
KR20230026312A (ko) 2020-06-17 2023-02-24 아르커스 바이오사이언시즈 인코포레이티드 Cd73 억제제의 결정형 및 이의 용도

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031320A1 (en) * 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
US20160129108A1 (en) * 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
CN108780084A (zh) * 2015-09-03 2018-11-09 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
CN108697719A (zh) * 2016-01-08 2018-10-23 艾库斯生物科学有限公司 胞外5′-核苷酸酶的调节剂及其用途
WO2017152085A1 (en) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
US20180200378A1 (en) * 2017-01-06 2018-07-19 Bicycle Therapeutics Limited Compounds for treating cancer
US20180215730A1 (en) * 2017-01-20 2018-08-02 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
WO2018187484A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
CN107286146A (zh) * 2017-07-05 2017-10-24 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4‑氨基嘧啶衍生物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEXANDER SCHOLZ等: "33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)", JOURNAL FOR IMMUNOTHERAPY OF CANCER, pages 1 - 398 *
JOEL LINDEN等: "Purine Release, Metabolism, and Signaling in the Inflammatory Response", ANNUAL REVIEW OF IMMUNOLOGY, pages 325 - 347 *

Also Published As

Publication number Publication date
JP7743309B2 (ja) 2025-09-24
JP2022527476A (ja) 2022-06-02
WO2020205527A1 (en) 2020-10-08
AU2020256098A1 (en) 2021-10-28
US20220211701A1 (en) 2022-07-07
KR20210144821A (ko) 2021-11-30
EP3947463A1 (en) 2022-02-09
US12310965B2 (en) 2025-05-27
US20250375447A1 (en) 2025-12-11
EP3947463A4 (en) 2022-12-21
CA3135487A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US20250375447A1 (en) Treatment of cancer utilizing an identified adenosine fingerprint
US20260115217A1 (en) Treatment of oncogene-driven cancers
JP7067804B2 (ja) がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
Wu et al. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma
JP2017533207A (ja) Ｓｌａｍｆ１アンタゴニスト及びその使用
US11633416B1 (en) Oral formulations of CD73 compounds
JP2024112878A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
KR20250024129A (ko) Vista의 수용체
WO2019089858A2 (en) Methods of assessing or monitoring a response to a cell therapy
HK40058244A (en) Treatment of cancer utilizing an identified adenosine fingerprint
CN117795341A (zh) 使用cd-40激动剂治疗癌症的方法
HK40056396A (en) Treatment of oncogene-driven cancers
US20260028407A1 (en) Modified anti-galectin-9 antibody and uses thereof
Wong Functional impact of high extracellular K+ on human T-cells
WO2025024258A2 (en) Ebv status as a predictor of response to immunotherapy
Geraghty The Role of Purinergic Signalling in Inflammatory Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058244

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211231